secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-10-02T20:16:12+00:00
Accession:  0001213900-26-106395
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Adial Pharmaceuticals adjourns 2026 annual meeting again over pending Nasdaq listing approval
--------------------------------------------------------------------------------

- Adial adjourned votes on Proposals 3, 4, 5 and 6 at its 2026 Annual Meeting because Nasdaq had not approved its Initial Listing Application.
- The reconvened Oct. 1, 2026 meeting was further adjourned; polls remain open and the meeting will reconvene Oct. 15, 2026 at 8:30 a.m. ET.
- The record date for the 2026 Annual Meeting remains Aug. 17, 2026, and stockholders who already voted on Proposals 3-6 need not act unless changing their vote.
- Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on at the Sept. 17, 2026 meeting; the definitive proxy statement was filed Aug. 24, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026106395/0001213900-26-106395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026106395/ea0307576-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-106395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer